ACRBP Antibody

What is ACRBP and why is it relevant to both reproductive and cancer research?

ACRBP (Acrosin Binding Protein) is a multifunctional protein initially identified in reproductive biology that has gained significant attention in cancer research. In reproductive biology, ACRBP is an acrosomal protein that maintains proacrosin (pro-ACR) as an enzymatically inactive zymogen in the acrosome and is involved in acrosome formation . ACRBP is expressed from primary spermatocytes to spermatozoa and catalyzes the conversion of proacrosin to acrosin, enabling the acrosome reaction .

In cancer research, ACRBP (also known as OY-TES-1 or CT23) is classified as a cancer/testis (CT) antigen. While normally expressed exclusively in the testis, ACRBP is abnormally expressed in various tumor types, including bladder, breast, liver, and lung carcinomas . Its expression is particularly upregulated in epithelial ovarian cancer (EOC), where it has been associated with paclitaxel resistance through its interaction with the nuclear mitotic apparatus (NuMA) protein . Additionally, ACRBP interacts with proteins like TUBB and enhances their function within pathways that influence the assembly and disassembly of the mitotic spindle during cell division .

This dual relevance makes ACRBP antibodies valuable tools for both reproductive biology and cancer research applications.

What are the primary applications for ACRBP antibodies in laboratory research?

ACRBP antibodies have diverse applications in research settings:

Research has demonstrated that ACRBP is predominantly localized in the cytoplasm of cancer cells, often showing a patchy staining pattern . In reproductive studies, ACRBP antibodies have been instrumental in tracking the processing of the 60-kDa precursor ACRBP-W into the 32-kDa mature ACRBP-C during spermatogenesis .

What are the different forms of ACRBP and how do antibodies recognize them?

ACRBP exists in multiple forms due to alternative splicing and post-translational processing:

When selecting ACRBP antibodies, researchers should consider which isoform(s) they need to detect. Some antibodies recognize epitopes common to multiple forms (like antibodies against ACRBP-W/ACRBP-C), while others are specific to particular variants (like antibodies against ACRBP-V5) .

How should researchers optimize ACRBP antibody staining protocols for different tissue types?

Optimizing ACRBP antibody staining requires tissue-specific considerations:

For testicular tissue:

• Fix tissues in 3.7% formaldehyde or paraformaldehyde

• Use acetone permeabilization (10 min at -20°C)

• Blocking in PBS with 5% BSA and 1% Tween is recommended

• Primary antibody incubation at 1:100-1:200 dilution overnight at 4°C

For cancer tissues (particularly ovarian cancer):

• Use heat-mediated antigen retrieval with citrate buffer (pH 6.0) for 15 minutes

• Block endogenous peroxidase activity with 0.3% H₂O₂ in PBS

• Use 1:200 dilution of rabbit polyclonal antibody against ACRBP (e.g., Abcam ab64809)

• For visualization, use HRP-conjugated secondary antibodies and 3,3'-diaminobenzidine (DAB)

For brain tumors (detecting ACRBP-V5a):

• Special primer design targeting the specific splice junction is crucial

• For antibody-based detection, validation of specificity for this variant is essential

The staining intensity can be scored as follows:

• (-): < 10% positive cells

• (+): 10-25% positive cells

• (++): 25-50% positive cells

• (+++): > 50% positive cells

What are the key considerations for detecting ACRBP in cancer research vs. reproductive biology studies?

In reproductive biology, ACRBP antibodies have been instrumental in demonstrating that ACRBP-V5 and ACRBP-C possess different domains capable of binding to distinct segments in the C-terminal region of proACR .

How can researchers effectively detect newly discovered ACRBP splice variants like ACRBP-V5a?

Detecting novel ACRBP splice variants like ACRBP-V5a requires specialized approaches:

• RNA-level detection:

  • Design primers that span the unique splice junctions

  • For ACRBP-V5a, forward primer 5′-TGAAGTCTCACCCACCACGATG-3′ and reverse primer 5′-GCTAGGAAAATGGGCTTCTCA-3′ can amplify a 600-bp segment between exons 4 and 5a

  • Use RT-PCR for initial detection and qPCR for quantification

• Protein-level detection:

  • Develop antibodies against unique peptide sequences at splice junctions

  • Validate antibody specificity using overexpression systems and knockdown controls

  • Use western blotting with appropriate molecular weight markers (ACRBP-V5a may have a distinct molecular weight from other variants)

• Expression analysis:

  • In brain tumors, ACRBP-V5a has been detected in 37% of samples (30% of astrocytomas, 33% of glioblastomas, and 48% of medulloblastomas)

  • Expression levels correlate significantly with tumor grade (p = 0.01) and tumor type (p = 0.02)

While specialized commercial antibodies for ACRBP-V5a are not yet widely available, researchers can develop custom antibodies based on the unique amino acid sequences at the novel splice junctions.

What are the optimal protocols for ACRBP immunoprecipitation to identify interacting partners?

For effective immunoprecipitation of ACRBP and identification of its interacting partners:

• Cell/Tissue Preparation:

  • Grow cells to confluence on 100-mm² dishes

  • Lyse cells in buffer containing 0.5% Triton X-100, 150 mM NaCl, and 0.5% deoxycholate

• Immunoprecipitation Procedure:

  • Incubate soluble lysate overnight with anti-ACRBP monoclonal antibody (e.g., UA199) precoupled to cyanogen-bromide agarose beads

  • Include mouse IgG-coupled beads as a negative control

  • Wash beads three times in lysis buffer with 500 mM NaCl

  • Elute bound proteins by adding sample buffer and boiling

  • Separate by 10% SDS-PAGE

• Interacting Partner Identification:

  • Use HPLC-mediated tandem mass spectroscopy for protein identification

  • This approach has successfully identified NuMA (Nuclear Mitotic Apparatus protein) as an ACRBP-interacting partner in a 180 kDa silver-stained band

  • The ACRBP-NuMA interaction has implications for paclitaxel resistance in epithelial ovarian cancer

• Validation:

  • Confirm interactions using reverse immunoprecipitation (IP with antibodies against the partner protein)

  • Use immunofluorescence to verify co-localization

  • Consider functional assays to demonstrate biological relevance of the interaction

How should researchers troubleshoot non-specific binding or weak signals when using ACRBP antibodies?

When optimizing IHC protocols:

• For formalin-fixed tissues, heat-mediated antigen retrieval with sodium citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins has proven effective

• For fluorescence applications, positive controls using tissues known to express ACRBP (e.g., testis) are essential

• Pre-immune serum should be used as a negative control to identify non-specific staining

What controls are essential for validating ACRBP antibody specificity in different experimental contexts?

Essential controls for validating ACRBP antibody specificity include:

• Positive Controls:

  • Human testis tissue (known to express high levels of ACRBP)

  • Cancer cell lines with confirmed ACRBP expression (e.g., ovarian cancer cell line PEO4)

  • Recombinant ACRBP protein for western blotting

• Negative Controls:

  • ACRBP knockout tissues/cells where available

  • Normal ovarian tissues (for cancer studies)

  • Pre-immune serum or isotype-matched control antibodies

  • Antibody pre-adsorption with immunizing peptide

• Specificity Validation:

  • siRNA knockdown of ACRBP (to confirm band disappearance in western blots)

  • Peptide competition assays (pre-incubating antibody with excess immunizing peptide)

  • Cross-validation with multiple antibodies targeting different epitopes

• Application-Specific Controls:

  • For IHC: Include testis as positive control and normal tissue as negative control

  • For IF: Include DAPI nuclear counterstain to verify cellular localization

  • For WB: Use molecular weight markers to confirm expected band sizes (60 kDa for ACRBP-W, 32 kDa for ACRBP-C)

Researchers studying Acrbp-knockout mouse models have effectively used these controls to confirm antibody specificity, showing the loss of 60/55- and 48/43-kDa doublets corresponding to ACRBP-W and ACRBP-V5 in testicular protein extracts .

How can ACRBP antibodies be utilized to study the role of ACRBP in cancer progression and chemoresistance?

ACRBP antibodies can be powerful tools for investigating cancer progression and chemoresistance:

What methodological approaches can optimize dual staining of ACRBP with other proteins?

For effective dual staining of ACRBP with other proteins:

• Antibody Selection:

  • Choose antibodies raised in different host species (e.g., rabbit anti-ACRBP with mouse anti-tubulin)

  • When using antibodies from the same species, consider directly conjugated antibodies or sequential staining protocols

• Protocol Optimization:

  • For dual IF staining with β-tubulin/pericentrin:

    • Fix cells in 3.7% formaldehyde

    • Permeabilize with 0.5% Triton X-100 for 10 minutes

    • Block in PBS-5% BSA-1% Tween

    • Incubate with primary antibodies (e.g., ACRBP at 1:100, β-tubulin at 1:100) for 1 hour

    • Apply Alexa-488 or 546 secondary antibodies (1:500) for 30 minutes at 37°C

  • For γ-tubulin co-staining:

    • After fixation, permeabilize in methanol at -20°C for 10 minutes

• Controls for Dual Staining:

  • Single-stained controls to assess bleed-through

  • Secondary antibody-only controls to detect non-specific binding

  • Sequential imaging to minimize cross-talk

• Analysis Approaches:

  • Quantify co-localization using Pearson's or Mander's coefficients

  • Analyze in specific cellular compartments or during different cell cycle phases

This dual staining approach has been used successfully to demonstrate co-localization of ACRBP with mitotic spindle components in cancer cells, supporting its role in cell division .

How can researchers utilize ACRBP antibodies to investigate splice variant functions in different pathological contexts?

To investigate ACRBP splice variant functions in different pathological contexts:

• Variant-Specific Detection:

  • Design RT-PCR primers spanning unique exon junctions for RNA detection

  • Develop antibodies against unique peptide sequences for protein detection

  • For ACRBP-V5a in brain tumors, use primers targeting the junction between exons 4 and 5a

• Expression Profiling:

  • Compare expression of different variants across:

    • Tumor types and grades

    • Normal vs. pathological tissues

    • Different stages of disease progression

  For example, ACRBP-V5a expression levels significantly correlate with brain tumor grade (p = 0.01) and tumor type (p = 0.02) .

• Functional Characterization:

  • Use variant-specific knockdown/overexpression

  • Analyze differential protein interactions using co-IP

  • Assess impact on cellular phenotypes (proliferation, migration, drug resistance)

• Clinical Correlation:

  • Compare variant expression with patient outcomes

  • Assess potential as biomarkers for specific disease subtypes

  • Evaluate potential as therapeutic targets

In reproductive biology, functional analysis has shown that ACRBP-V5 and ACRBP-C possess different domains capable of binding to distinct segments in the C-terminal region of proACR, suggesting they may have differentiated functions in sperm development . Similar approaches can be applied to investigate the functions of variants like ACRBP-V5a in cancer contexts.

How might ACRBP antibodies contribute to cancer immunotherapy development?

ACRBP's status as a cancer-testis (CT) antigen makes it relevant for immunotherapy research:

• Diagnostic and Prognostic Applications:

  • ACRBP antibodies can help identify patients with ACRBP-expressing tumors who might benefit from targeted immunotherapies

  • The presence of anti-ACRBP antibodies in patient sera (28.5% of ovarian cancer patients) indicates natural immunogenicity

• Therapeutic Target Validation:

  • IHC with ACRBP antibodies can validate expression in tumor tissues

  • Quantification of ACRBP in different tumor compartments can guide therapeutic approaches

  • Data shows that ACRBP is highly expressed in 70.7% (46/65) of ovarian cancer samples

• Therapy Monitoring:

  • ACRBP antibodies can track changes in ACRBP expression during treatment

  • ELISA-based detection of anti-ACRBP antibodies could monitor immune responses to treatment

• Combination Therapy Stratification:

  • ACRBP expression correlates with chemosensitivity in ovarian cancer

  • This could inform selection of patients for combination immunotherapy/chemotherapy approaches

The restricted expression pattern of ACRBP (normally only in testis) and its high specificity to cancer cells makes it a promising target for tumor-specific antigen-based immunotherapy, particularly for patients with ovarian cancer .

What are the latest methodological advances in using ACRBP antibodies for liquid biopsy applications?

Recent advances in using ACRBP antibodies for liquid biopsy include:

• Serum ACRBP Detection:

  • ELISA-based assays can detect ACRBP antigen in serum samples from cancer patients

  • This approach has shown promise in ovarian cancer diagnostics

• Anti-ACRBP Autoantibody Detection:

  • Serological analysis has detected anti-ACRBP antibodies in 28.5% (16/56) of ovarian cancer patients but not in healthy donors

  • The ROC curve analysis showed an area under the curve of 0.802 (95% CI: 0.708–0.876)

  • Sensitivity and specificity were 85.71% and 55.0%, respectively

• Circulating Tumor Cell (CTC) Analysis:

  • ACRBP antibodies can be used to identify CTCs expressing this cancer-testis antigen

  • This may help identify patients with specific tumor subtypes

• Methodological Considerations:

  • Pre-analytical factors (sample collection, processing, storage) significantly impact results

  • Standardization of ELISA protocols is essential for reproducibility

  • Multiplexing with other cancer biomarkers increases diagnostic accuracy

How can machine learning approaches enhance the specificity and sensitivity of ACRBP antibody-based diagnostics?

Machine learning (ML) can significantly improve ACRBP antibody-based diagnostics:

• Enhanced Image Analysis for IHC:

  • ML algorithms can standardize interpretation of ACRBP staining patterns

  • Quantitative assessment of staining intensity and distribution

  • Automatic identification of cellular compartments with ACRBP expression

• Multiparameter Biomarker Panels:

  • ML can identify optimal combinations of ACRBP with other biomarkers

  • Integration of ACRBP expression/antibody data with clinical parameters

  • This approach may overcome the limited specificity (55.0%) reported for ACRBP antibody alone

• Predictive Models for Treatment Response:

  • ML algorithms can correlate ACRBP expression patterns with treatment outcomes

  • This is particularly relevant given ACRBP's association with chemosensitivity in ovarian cancer

• Out-of-Distribution Prediction Improvement:

  • Active learning approaches can enhance antibody-antigen binding prediction in library-on-library settings

  • Recent research demonstrated that active learning algorithms reduced the number of required antigen mutant variants by up to 35%

The best active learning algorithms have been shown to speed up the learning process by 28 steps compared to random baselines, demonstrating that these approaches can improve experimental efficiency in antibody research .